This biotech stock has 'multiblockbuster IBD opportunity': analyst

September 10, 2026 5:00 PM

Goldman Sachs has initiated coverage of a biotech name with a Buy rating in a note this week, describing the ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found